SOAT1 and primary biliary cholangitis: To address this issue, we chose ruxolitinib, an FDA-approved JAK1/2 inhibitor that can block both the type I and type II IFN-induced JAK/STAT pathways, and examined its effects using the established ARE-Del mouse model of PBC.